Abstract
The efficacy and safety of sitagliptin as an add-on therapy to glimepiride were evaluated in a multicenter, randomized, double-blind, placebo-controlled study, followed by an uncontrolled open-label period, in Japanese patients with type 2 diabetes who had inadequate glycemic control on diet/exercise therapy and glimepiride monotherapy. During the initial double-blind period, sitagliptin (50 mg q.d.) or placebo was added to ongoing glimepiride [1–6 mg a day] for 12 weeks. This was followed by a 40-week period of open-label administration of sitagliptin 50 (or 100 mg q.d. after up-titration) added to continued glimepiride. For the placebo-controlled, 12-week double-blind period, the difference between the two treatment groups in the least-squares mean change from baseline and its 95% confidence interval (CI) for HbA1c was −0.76% (−0.98, −0.55, p < 0.001) in favor of the addition of sitagliptin. The mean changes from baseline in 2-h post-meal glucose and fasting plasma glucose were significantly lower in the sitagliptin group compared with the placebo group: −43.2 mg/dL (−58.9, −27.5) and −18.1 mg/dL (−25.7, −10.5), respectively (both p < 0.001). During the initial 12 weeks, the incidence of adverse experiences was similar in both treatment groups with comparable, low incidences of hypoglycemia and no differences in weight change between groups. The glycemic changes from baseline following the addition of sitagliptin to glimepiride remained generally stable through 52 weeks. The addition of sitagliptin improved glycemic parameters including HbA1c and was generally well tolerated through 52 weeks in Japanese patients with type 2 diabetes who had inadequate glycemic control with diet/exercise and glimepiride monotherapy.
Similar content being viewed by others
Notes
In this manuscript, the value for HbA1c(%) is estimated as an NGSP (National Glycohemoglobin Standardization Program) equivalent value (%) calculated by the formula HbA1c (%) = HbA1c [Japan Diabetes Society (JDS)] (%) + 0.4% considering the relational expression of HbA1c(JDS)(%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) [8].
References
Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab. 2007;9:153–65.
Prato SD, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006;55:S20–7.
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.
Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels fromcells and extrapancreatic tissues. Metabolism. 2000;49:3–6.
Hermansen K, Kipnes M, Lou E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepride and metformin. Diabetes Obes Metab. 2007;9:733–45.
Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66:S37–43.
Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, Takagi H, Awai K. The status of diabetes control and antidiabetic drug therapy in Japan—a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract. 2006;73:198–204.
The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53:450–67.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
Turner RC, Rudenski AS, Matthews DR, Levy JC, O’Rahilly SP, Hosker JP. Application of structural model of glucose–insulin relations to assess beta-cell function and insulin sensitivity. Horm Metab Res Suppl. 1990;24:66–71.
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–7.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.
Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Contemporary analysis of secondary failure of successful sulfonylurea therapy. Endocr Pract. 2007;13:37–44.
Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79:291–8.
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564–71.
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–43.
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added on ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–68.
Committee on the Appropriate Use of Incretin-based Therapies (GLP-1 Mimetics or DPP-4 Inhibitors). Notice from the committee. Japan Diabetes Society; 2010. http://www.jds.or.jp/jds_or_jp0/uploads/photos/666.pdf. Accessed 20 Oct 2010.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203.
Acknowledgements
This study was sponsored by Ono Pharmaceutical Co., Ltd. and MSD K. K. The authors would like to thank M. Kawashima and M. Odani (Ono Pharmaceutical Co., Ltd.) and William V. Taggart (Merck, Sharp and Dohme) for their contributions to the writing and editing of this manuscript.
Author information
Authors and Affiliations
Corresponding author
MK-0431/ONO5435-09, MSD K. K. 056 Primary Investigators’ list
MK-0431/ONO5435-09, MSD K. K. 056 Primary Investigators’ list
Shinji Taneda (Manda Memorial Hospital), Shin Aoki (Aoki Clinic), Hideo Manaka and Hiroshi Ohnuma (Sagae City Hospital), Nobuyuki Miyake (Shirakawa Hospital), Hajime Ishii (Kashinoki Internal Medicine Clinic), Hisamoto Kuroda (Green Clinic), Shuichi Fukuda (Wakakusa Clinic), Kou Ishikawa and Keiji Mikami and Takahiko Tokuyama (Omigawa General Hospital), Nobuichi Kuribayashi (Misaki Naika Clinic), Tadasu Kasahara (Johsai Hospital), Matsuura Yasuhiko (Matsuura Clinic), Akifumi Kushiyama and Yukiko Ohnishi (Marunouchi Hospital attached to the Institute for Adult Diseases, Asahi Life Foundation), Yoshitaka Aiso (Aiso Clinic), Masaharu Morohoshi (Sanraku Hospital Clinic For Lifestyle-Related Disease), Tetsuya Morishita (Yamamoto Kinen Hospital), Keiko Arai (Arai Clinic), Michio Nakagawa (Matsumoto Nakagawa Hospital), Yukiko Kato (Kamiiida daiichi General Hospital), Tetsuhiro Yamada (Yamada Clinic), Shigeo Wada (Wada Clinic), Shizuo Kajiyama (Kajiyama Clinic), Katsuhiro Zen (Seijukai Hospital), Takamichi Nishimura (Nishimura Naika Clinic), Kazuo Ichikawa (Center Clinic), Hiroshi Miki and Shigetoshi Hosaka (Hiroshima Teishin Hospital), Tomokazu Kawamura (Hiroshima City Hospital), Toshiki Fukui (NTT West Takamatsu Hospital), Kazuya Yoshii (Izumino Hospital), Kiyohide Nunoi (St. Mary’s Hospital), Hironori Yamasaki (Nagasaki University Hospital), Kazunari Matsumoto (Sasebo Chuo Hospital), Kiichiro Higashi (National Hospital Organization Kumamoto Medical Center), Kaku Tsuruzoe (Kumamoto University Hospital), Chuwa Tei (Kagoshima University Medical and Dental Hospital).
About this article
Cite this article
Tajima, N., Kadowaki, T., Odawara, M. et al. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int 2, 32–44 (2011). https://doi.org/10.1007/s13340-011-0022-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-011-0022-2